Apolipoprotein E (apoE) plays a critical role in lipid transport and brain homeostasis, with APOE ε4 allele representing the strongest genetic risk factor for late-onset Alzheimer's disease. This category covers therapeutic approaches targeting apoE biology and related lipid transport pathways.
The APOE gene (chromosome 19q13.32) encodes a 299-amino acid glycoprotein produced primarily by astrocytes in the brain. Three common alleles (ε2, ε3, ε4) encode proteins with different functional properties:
| Allele | Frequency | Effect |
|---|---|---|
| APOE ε2 | ~8% | Protective, reduces AD risk |
| APOE ε3 | ~78% | Normal function, neutral risk |
| APOE ε4 | ~14% | Risk factor, increases AD risk 3-4x (heterozygous), 10-12x (homozygous) |
Mechanism: Antibodies targeting apoE can reduce amyloid burden by enhancing microglial clearance of Aβ-apoE complexes and preventing plaque formation.
| Approach | Developer | Status | Notes |
|---|---|---|---|
| Anti-apoE antibodies | Various | Preclinical | Target Aβ-apoE complexes |
| ApoE fragment vaccines | Research | Early | Stimulate anti-apoE antibodies |
Lexeo Therapeutics is developing LX1001, an AAV-based gene therapy delivering protective APOE2 to APOE4 homozygotes. This approach aims to reduce AD risk in high-risk individuals.
| Program | Developer | Approach | Status |
|---|---|---|---|
| LX1001 | Lexeo Therapeutics | AAV-APOE2 delivery | Phase 1/2 |
ATP-binding cassette transporters ABCA1 and ABCG1 regulate cellular cholesterol efflux and apoE lipidation. Enhancing their function may improve apoE function and Aβ clearance.
| Target | Compound | Developer | Status |
|---|---|---|---|
| ABCA1 | CSK264 | Research | Preclinical |
| ABCG1 | Small molecules | Research | Preclinical |
Denali Therapeutics is developing programs targeting APOE biology and lipid homeostasis:
| Program | Target | Approach | Status |
|---|---|---|---|
| DNL351 | ABCA1 modulator | Small molecule | Preclinical |
| APOE programs | Various | Multiple | Discovery |
While primarily an OGA inhibitor, Lilly's LY3372689 has additional activities affecting lipid metabolism and may provide benefits through multiple mechanisms.
| Program | Type | Phase | Indication |
|---|---|---|---|
| LX1001 | Gene therapy | Phase 1/2 | AD (APOE4 homo) |